Coronary Stents Market Report: Drivers, Restraints and Opportunities, Trends and Forecasts to 2023

  • Product Code:
  • Published Date:
    Mar 2019
  • Region:
  • Pages:
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Infoholic Research
Indian Market Scenario for Coronary Stent
Cardiovascular diseases account for closely 25% of the deaths in India among the age group of 25 and 70 years. The total number of percutaneous coronary interventions (PCI) is growing gradually at a mid CAGR. In 2016, 495,000 PCI procedures were carried out in India, using 594,000 stents (with an average of 1.2 stents per procedure). Out of these, 80% of the procedures performed used drug-eluting stents (DES), with over 60% of the stents being imported. These MNCs classically go through a supply chain, where the distributors manage the procurement and storage of the stents, and later ship them to the hospitals on requirement. The hospitals add their share of profit to the procured price and bill accordingly. This led to a wide gap between the actual cost of the stent and the selling price to the patient. The average selling price (ASP) of a bare metal stent (BMS) used to be as high as Rs.45,000 ($670) and the drug-eluting stents were priced more than Rs.120,000 ($1,800). This generated a profit between 270% to 1,000%.

Ceiling fixed prices for coronary stents
The notification by National Pharmaceutical Pricing Policy categorizes the stents into bare metal stents (BMS) and drug-eluting stents (DES). Bare metal stents are not to be priced more than Rs.7,260 ($110), while drug-eluting stents should be priced below Rs.29,600 ($450). This is 40% lesser than the previous prices.
Manufacturer Brand Prices (Rs)
Abbott Laboratories Aborb/ Absorb GT1 31,689
Abbott Laboratories Xience Alpine 31,689
Abbott Laboratories Xience Prime 24,675
Abbott Laboratories Xience Pro 24,675
Abbott Laboratories Xience V 24,675
Abbott Laboratories Xience Xpedition 31,689
Boston Scientific Corporation Promus Element
Boston Scientific Corporation Promus Premier 31,689
Boston Scientific Corporation Synergy 31,689
Meril Life Science Biomime 23,625
Sahajanand Medical Technologies Supraflex 23,289
Biotronik Orsiro 31,689
Vascular Concept Limited Pronova XR 31,689

Does this also include imported stents?
The notification makes no discrepancy between branded or unbranded stents, locally manufactured or imported stents. Any stent sold in the Indian market cannot be charged more than Rs.29,600 ($450), though there is the addition of local taxes to these prices. The manufacturers with higher selling price than the cap will have to reduce the prices of their stents, while those selling at lesser prices should maintain their original MRP.
Indian Market Scenario
The Indian coronary stent market is worth currently around $500 million and is anticipated to grow many times in the future due to the growing number of diabetes and hypertension cases. International stent manufacturers, who hold around 60% of the market, are unhappy with the price capping. Hence, they are planning to with withdraw their advanced products from the Indian market and are planning not to bring in the new-generation products in the future. This change may affect the procedural outcomes, especially in complex cases. Thus, India is expected to face more challenges in the future. Abbott requested the removal of its Alpine and Absorb stents from the Indian market, while Medtronic requested to withdraw its Onyx stents. Following them, Boston petitioned for the removal of synergy stents. But their request was rejected by the Indian authorities. This has given a better opportunity for the domestic manufacturers to increase their market share which currently hold less than 40% share.
Regulatory changes for price control
• In July 2016, the coronary stents were included in the National List of Essential Medicines, 2015 (NLEM, 2015) by the Ministry of Health and Family Welfare.
• In December 2016, the coronary stents were given the status of scheduled formulation as in the Drug Price Control Order 2013, by the Department of Pharmaceuticals.

Coronary Stents – competitive scenario
The coronary stents market is segmented into bare metal stents, drug-eluting stents, and bioabsorbable stents. Approximately 90% of all the percutaneous coronary intervention (PCI) surgeries use a coronary stent. Thus, drug-eluting stents hold the major share in the market. The highest growth rate is expected in the bioresorbable stents due to the advantages of the polylactic acid material. The market is also witnessing various mergers, acquisitions, and collaborations among the top players, which is defining the future of the Global Coronary Stents Market.
The exit of Johnson and Johnson from the coronary stents market has provided an opportunity for many players to strengthen their market share. Abbott Laboratories, Medtronic, and Boston Scientific Corporation are the market leaders in the global coronary stents market in 2016. The top three market players are estimated to hold more than 60% share of the market in 2016. Abbott Laboratories emerged to be the global leader, while Boston Scientific Corporation dominated the market in Brazil and other emerging Latin American countries.
Global coronary stents market growth
The Global Coronary Stents Market is expected to grow at a CAGR of 6.1% during the forecast period 2017–2023. The market is analyzed based on regions and verticals. The market in emerging regions, mergers and acquisitions, and the increase in clinical trials are some factors providing opportunities for the market growth during the forecast period.
Table of Contents
1 Industry Outlook 8
1.1 Industry Overview 8
1.2 Industry Trends 8
1.3 PEST Analysis 9
2 Report Outline 9
2.1 Report Scope 9
2.2 Report Summary 10
2.3 Research Methodology 11
2.4 Report Assumptions 11
3 Market Snapshot 12
3.1 Total Addressable Market 12
3.2 Segmented Addressable Market 12
3.3 Related Markets 13
3.3.1 Interventional Cardiology 13
3.3.2 Peripheral Vascular Stents 13
3.3.3 Atherectomy 14
4 Market Outlook 15
4.1 Market Definition – Infoholic Research 15
4.2 Causes for Coronary Heart Disease 15
4.3 Market Segmentation 15
4.4 Porter 5(Five) Forces 15
5 Market Characteristics 16
5.1 Evolution 16
5.2 Stents Platforms 17
5.3 Market Dynamics 18
5.3.1 Drivers 18 Increasing prevalence of cardiovascular diseases 18 Increasing aging population 18 Growing acceptance for minimally invasive endovascular surgeries 19
5.3.2 Opportunities 19 Market expansion opportunities in emerging nations 19 Increasing clinical trials 19
5.3.3 Restraints 19 Stringent regulations for approval 19 High cost of treatment associated with stent implants 20 Availability of alternative treatment procedure 20
5.4 DRO – Impact Analysis 20
5.5 Key Stakeholders 21
6 Coronary Stents Pipeline 22
6.1 Overview 22
7 Types: Market Size and Analysis 25
7.1 Overview 25
7.2 Bare Metal Stents (BMS) 25
7.3 Drug Eluting Stents 26
7.4 Bio-absorbable Stents 27
8 End-users: Market Size and Analysis 28
8.1 Overview 29
8.2 Hospitals 29
8.3 Ambulatory Surgical Centers (ASCs) 29
8.4 Cardiac Centers 30
9 Regions: Market Size and Analysis 30
9.1 Overview 30
9.2 North America 31
9.2.1 US 32
9.2.2 Canada 33
9.3 Europe 33
9.3.1 UK 34
9.3.2 Germany 34
9.3.3 France 35
9.4 Asia Pacific 35
9.4.1 Japan 36
9.4.2 China 36
9.4.3 India 36
9.5 Rest of the World 37
9.5.1 Africa 38
9.5.2 Brazil 38
10 Competitive Landscape 38
10.1 Overview 38
11 Vendors Profile 41
11.1 Abbott Laboratories (Abbott) 41
11.1.1 Overview 41
11.1.2 Business Unit 45
11.1.3 Geographic Presence 46
11.1.4 Business Focus 46
11.1.5 SWOT Analysis 47
11.1.6 Business Strategy 47
11.2 Boston Scientific Corp. (Boston) 48
11.2.1 Overview 48
11.2.2 Business Units 51
11.2.3 Geographic Presence 52
11.2.4 Business Focus 52
11.2.5 SWOT Analysis 53
11.2.6 Business Strategies 53
11.3 B. Braun Melsungen AG 54
11.3.1 Overview 54
11.3.2 Business Units 56
11.3.3 Geographic Presence 57
11.3.4 Business Focus 57
11.3.5 SWOT Analysis 58
11.3.6 Business Strategies 58
11.4 Medtronic Plc 59
11.4.1 Overview 59
11.4.2 Business Units 66
11.4.3 Geographic Presence 67
11.4.4 Business Focus 68
11.4.5 SWOT Analysis 69
11.4.6 Business Strategies 69
11.5 MicroPort Scientific Corporation 70
11.5.1 Overview 70
11.5.2 Business Units 73
11.5.3 Geographic Presence 74
11.5.4 Business Focus 75
11.5.5 SWOT Analysis 75
11.5.6 Business Strategies 76
12 Companies to Watch For 76
12.1 Terumo Corp. 77
12.1.1 Overview 77
12.2 Biosensors International Group 79
12.2.1 Overview 79
12.3.1 Overview 80
12.4 Meril Life Science 81
12.4.1 Overview 81
12.5 STENTYS S.A. 82
12.5.1 Overview 82
12.5.2 Overview 82
Annexure 84
Abbreviations 84

Please enter your personal details below
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
Abbott Laboratories, Boston Scientific Corporation, Medtronic PLC, B. Braun Melsungen AG, Terumo Corporation, Biotronik SE & Co. KG, Stentys SA, MicroPort Scientific Corporation, and Meril Life Science, and other predominant
Please enter your personal details below
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports